{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:03:31Z","timestamp":1784847811146,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12185-022-03388-8","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T14:02:43Z","timestamp":1653919363000},"page":"612-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed\/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-113X","authenticated-orcid":false,"given":"Hideki","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitose","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"3388_CR2","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339\u201347.","journal-title":"J Clin Oncol"},{"key":"3388_CR3","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a children\u2019s oncology group study [corrected]. J Clin Oncol. 2008;26:3971\u20138.","journal-title":"J Clin Oncol"},{"key":"3388_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1182\/blood.V71.5.1480.1480","volume":"71","author":"DR Boue","year":"1988","unstructured":"Boue DR, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood. 1988;71:1480\u20136.","journal-title":"Blood"},{"key":"3388_CR5","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, Coiffier B, Cruczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of b-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085\u201393.","journal-title":"J Clin Oncol"},{"key":"3388_CR6","first-page":"875","volume":"118","author":"S O\u2019Brien","year":"2011","unstructured":"O\u2019Brien S. Inotuzumab ozogamicin (I0), a CD22 monoclonal antibody conjugated to calicheamicin, is active in refractory-relapse acute lymphocytic leukemia (R-R ALL). Blood (ASH Annual Meeting). 2011;118:875.","journal-title":"Blood (ASH Annual Meeting)"},{"key":"3388_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403\u201311.","journal-title":"Lancet Oncol"},{"key":"3388_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"3388_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"H Kantarjian","year":"2019","unstructured":"Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow up from the randomized, phase 3 INO-VATE Study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"3388_CR10","unstructured":"BESPONSA\u24c7 (inotuzumab ozogamicin) Package Insert. Revised 5\/2018. Initial US approval: 2017. Philadelphia: Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc; 2018."},{"key":"3388_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/pbc.24721","volume":"61","author":"M Rytting","year":"2014","unstructured":"Rytting M, Triche L, Thomas D, O\u2019Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:369\u201372.","journal-title":"Pediatr Blood Cancer"},{"key":"3388_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"3388_CR13","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"3388_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, Incidence, and Predisposing Factors. Hepatology. 1984;4:116\u201322.","journal-title":"Hepatology"},{"key":"3388_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/sj.leu.2404535","volume":"21","author":"VH Van der Velden","year":"2007","unstructured":"Van der Velden VH, Panzer-Gr\u00fcmayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnosis for childhood acute lymphoblastic leukemia in multi-center setting. Leukemia. 2007;21:706\u201313.","journal-title":"Leukemia"},{"key":"3388_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/pbc.22620","volume":"55","author":"K Yamaji","year":"2010","unstructured":"Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese childhood cancer and leukemia study group. Pediatr Blood Cancer. 2010;55:1287\u201395.","journal-title":"Pediatr Blood Cancer"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Non-parametric estimation for uncomplete observations. J Am Stat Assc. 1958;53:457\u201381.","journal-title":"J Am Stat Assc"},{"key":"3388_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles-Diaz","year":"2014","unstructured":"Robles-Diaz M, Lucena IM, Kaplowitz N, Stephens C, Medina-C\u00e1liz I, Gonz\u00e1lez-Jimenez A, et al. Use of Hy\u2019s Law and a New composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147:109\u201318.","journal-title":"Gastroenterology"},{"key":"3388_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, Malone A, D\u00edaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137:1582\u201390.","journal-title":"Blood"},{"key":"3388_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02029","author":"MM O\u2019brien","year":"2022","unstructured":"O\u2019brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of Inotuzumab Ozogamicin in Children and Adolescents with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children\u2019 Oncology Group Protocol AALL1621. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.21.02029 (Online January 18, 2022).","journal-title":"J Clin Oncol"},{"key":"3388_CR22","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","volume":"118","author":"N Hijiya","year":"2011","unstructured":"Hijiya N, Thompson B, Isakoff MS, Silverman LB, Steinherz PG, Borowwitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043\u20139.","journal-title":"Blood"},{"key":"3388_CR23","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/pbc.26129","volume":"63","author":"W Sun","year":"2016","unstructured":"Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, et al. Treatment-related adversew events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed\/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:1943\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884\u201392.","journal-title":"Leukemia"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of Inotuzumab ozogamicin in relapse\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46:211\u201322.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3388_CR26","unstructured":"Pfizer Japan Inc. Inotuzumab ozogamicin Common Technical Document Module 2.7.1 [in Japanese]. https:\/\/www.pmda.go.jp\/drugs\/2018\/P20180209001\/index.html. Accessed: 23 Dec 2021"},{"key":"3388_CR27","unstructured":"https:\/\/www.researchgate.net\/profile\/Gregor-Verhoef\/publication\/42389650_Safety_Pharmacokinetics_and_Preliminary_Clinical_Activity_of_Inotuzumab_Ozogamicin_a_Novel_Immunoconjugate_for_the_Treatment_of_B-Cell_Non-Hodgkin%27s_Lymphoma_Results_of_a_Phase_I_Study\/links\/568bae6608aebccc4e1c0286\/Safety-Pharmacokinetics-and-Preliminary-Clinical-Activity-of-Inotuzumab-Ozogamicin-a-Novel-Immunoconjugate-for-the-Treatment-of-B-Cell-Non-Hodgkins-Lymphoma-Results-of-a-Phase-I-Study.pdf"},{"key":"3388_CR28","unstructured":"https:\/\/onlinelibrary-wiley-com.eu1.proxy.openathens.net\/doi\/pdfdirect\/10.1111\/j.1349-7006.2010.01601.x"},{"key":"3388_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/cts.12841","volume":"14","author":"J Chen","year":"2021","unstructured":"Chen J, Haughey M, Vandendries E, DeAngelo DJ, Kantarjian HM, Ruiz-Garcia A. Characterization of the relationship of Inotuzumab Ozogamicin exposure with efficacy and safety end points in adults with relapsed or refractory acute lymphoblastic leukemia. Clin Transl Sci. 2021;14:184\u201393.","journal-title":"Clin Transl Sci"},{"key":"3388_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","volume":"38","author":"H Inaba","year":"2019","unstructured":"Inaba H, Pui CH. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019;38:595\u2013610.","journal-title":"Cancer Metastasis Rev"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Binatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"3388_CR32","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s12325-019-00991-w","volume":"36","author":"I Proskorovsky","year":"2019","unstructured":"Proskorovsky I, Su Y, Fahrbach K, Vandendries E, Pag\u00e9 V, Onyekwere U, et al. Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia. Adv Ther. 2019;36:2147\u201360.","journal-title":"Adv Ther"},{"key":"3388_CR33","doi-asserted-by":"publisher","first-page":"28718","DOI":"10.1002\/pbc.28718","volume":"68","author":"CF Contreras","year":"2021","unstructured":"Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK. Clinical utilization of binatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68:28718.","journal-title":"Pediatr Blood Cancer"},{"key":"3388_CR34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjh.16647","volume":"190","author":"JL Fuster","year":"2020","unstructured":"Fuster JL, Molinos-Quintana A, Fuentes C, Fernadez JM, Velasco P, Pascual T, et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br J Haematol. 2020;190:764\u201371.","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1007\/s12185-023-03584-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03388-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T12:08:32Z","timestamp":1679400512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03388-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-023-03584-0","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-023-03584-0","URL":"https:\/\/doi.org\/10.1007\/s12185-023-03584-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study related COI would be reviewed and approved by COI review board prescribed by Nagoya Medical Center based on the self-declaration form of the person in charge such as the attending physician. The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}